CN116075499B - 具有前药特性的新型脱磷酸裸盖菇素衍生物 - Google Patents

具有前药特性的新型脱磷酸裸盖菇素衍生物

Info

Publication number
CN116075499B
CN116075499B CN202180051296.8A CN202180051296A CN116075499B CN 116075499 B CN116075499 B CN 116075499B CN 202180051296 A CN202180051296 A CN 202180051296A CN 116075499 B CN116075499 B CN 116075499B
Authority
CN
China
Prior art keywords
dephosphorylated
compound
ethyl
nupharicin
galectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180051296.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN116075499A (zh
Inventor
M·格里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Compass Pathfinder Ltd
Original Assignee
Compass Pathfinder Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102020121965.2A external-priority patent/DE102020121965A1/de
Application filed by Compass Pathfinder Ltd filed Critical Compass Pathfinder Ltd
Priority to CN202510790017.XA priority Critical patent/CN120904096A/zh
Publication of CN116075499A publication Critical patent/CN116075499A/zh
Application granted granted Critical
Publication of CN116075499B publication Critical patent/CN116075499B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180051296.8A 2020-08-21 2021-08-23 具有前药特性的新型脱磷酸裸盖菇素衍生物 Active CN116075499B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510790017.XA CN120904096A (zh) 2020-08-21 2021-08-23 具有前药特性的新型脱磷酸裸盖菇素衍生物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102020121965.2 2020-08-21
DE102020121965.2A DE102020121965A1 (de) 2020-08-21 2020-08-21 Neuartige Derivate des Psilocins mit Prodrug-Eigenschaften
US202063118842P 2020-11-27 2020-11-27
US63/118,842 2020-11-27
PCT/EP2021/073303 WO2022038299A1 (en) 2020-08-21 2021-08-23 Novel psilocin derivatives having prodrug properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510790017.XA Division CN120904096A (zh) 2020-08-21 2021-08-23 具有前药特性的新型脱磷酸裸盖菇素衍生物

Publications (2)

Publication Number Publication Date
CN116075499A CN116075499A (zh) 2023-05-05
CN116075499B true CN116075499B (zh) 2025-07-25

Family

ID=77739049

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180051296.8A Active CN116075499B (zh) 2020-08-21 2021-08-23 具有前药特性的新型脱磷酸裸盖菇素衍生物
CN202510790017.XA Pending CN120904096A (zh) 2020-08-21 2021-08-23 具有前药特性的新型脱磷酸裸盖菇素衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510790017.XA Pending CN120904096A (zh) 2020-08-21 2021-08-23 具有前药特性的新型脱磷酸裸盖菇素衍生物

Country Status (14)

Country Link
US (1) US20230295086A1 (https=)
EP (1) EP4200279A1 (https=)
JP (1) JP2023538402A (https=)
KR (1) KR20230054397A (https=)
CN (2) CN116075499B (https=)
AU (1) AU2021328726A1 (https=)
BR (1) BR112023003153A2 (https=)
CA (1) CA3188636A1 (https=)
CO (1) CO2023003282A2 (https=)
GB (2) GB2632056B (https=)
IL (1) IL300455A (https=)
MX (1) MX2023002133A (https=)
WO (1) WO2022038299A1 (https=)
ZA (1) ZA202301693B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US12414936B2 (en) * 2017-02-09 2025-09-16 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
US12343328B2 (en) 2020-12-09 2025-07-01 Caamtech, Inc. Dialkyl tryptamines and their therapeutic uses
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
WO2023023347A1 (en) * 2021-08-20 2023-02-23 Terran Biosciences Inc. Prodrugs and derivatives of psilocin and uses thereof
EP4452939A4 (en) * 2021-12-24 2025-12-10 Kuleon Llc SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
US11707447B1 (en) 2022-03-18 2023-07-25 Enveric Biosciences Canada Inc. C4-carbonothioate-substituted tryptamine derivatives and methods of using
EP4493544A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE
WO2023201293A2 (en) * 2022-04-13 2023-10-19 Caamtech, Inc. Tryptamine derivatives
EP4522167A1 (en) * 2022-05-10 2025-03-19 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
WO2023219789A1 (en) * 2022-05-10 2023-11-16 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
JP2025527296A (ja) * 2022-08-05 2025-08-20 マインドセット ファーマ インコーポレイテッド セロトニンに関する障害の治療に有用であるセロトニン作動薬としての３－エチルアミノ－インドール二量体
CA3261814A1 (en) * 2022-08-05 2024-02-08 Mindset Pharma Inc. 3-PYRROLIDINE-INDOLE DIMERS USED AS SEROTONINERGY AGENTS USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH THESE
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
WO2024055106A1 (en) * 2022-09-12 2024-03-21 Bionxt Solutions Inc. Amino acid and carbohydrate psilocin derivatives
US20240269113A1 (en) * 2023-01-24 2024-08-15 Compass Pathfinder Limited 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
EP4592276A1 (en) 2024-01-29 2025-07-30 Universität Heidelberg Novel acyloxymethyl prodrugs of psilocin and related 4-hydroxytryptamines obtained by an efficient synthetic approach

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740728A (zh) * 2017-02-09 2020-01-31 卡马技术有限责任公司 包含裸头草碱衍生物的组合物和方法
WO2021155470A1 (en) * 2020-02-04 2021-08-12 Mindset Pharma Inc. Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075992A (en) 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
CH386442A (de) 1959-03-18 1965-01-15 Ciba Geigy Verfahren zur Herstellung neuer 7-Aza-benzimidazole
AU2005300045A1 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
JP2010507585A (ja) * 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
WO2023023347A1 (en) * 2021-08-20 2023-02-23 Terran Biosciences Inc. Prodrugs and derivatives of psilocin and uses thereof
US20240269113A1 (en) * 2023-01-24 2024-08-15 Compass Pathfinder Limited 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES
US20250066394A1 (en) * 2023-08-25 2025-02-27 Compass Pathfinder Limited 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740728A (zh) * 2017-02-09 2020-01-31 卡马技术有限责任公司 包含裸头草碱衍生物的组合物和方法
WO2021155470A1 (en) * 2020-02-04 2021-08-12 Mindset Pharma Inc. Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin;David E. 等;《Synthesis》;19990601;第1999卷(第6期);第935-938页 *
Synthetic Studies of Psilocin Analogs Having Either a Formyl Group or Bromine Atom at the 5- or 7-Position;Fumio YAMADA 等;《Chem.Pharm.Bull.》;20020101;第50卷(第1期);第92-99页 *

Also Published As

Publication number Publication date
GB2632056A (en) 2025-01-22
WO2022038299A1 (en) 2022-02-24
EP4200279A1 (en) 2023-06-28
GB202412449D0 (en) 2024-10-09
JP2023538402A (ja) 2023-09-07
GB2613993A (en) 2023-06-21
ZA202301693B (en) 2026-01-28
IL300455A (en) 2023-04-01
GB2613993B (en) 2024-10-09
MX2023002133A (es) 2023-05-12
GB2632056B (en) 2025-04-16
AU2021328726A1 (en) 2023-03-02
CN120904096A (zh) 2025-11-07
KR20230054397A (ko) 2023-04-24
BR112023003153A2 (pt) 2023-04-04
US20230295086A1 (en) 2023-09-21
CA3188636A1 (en) 2022-02-24
CO2023003282A2 (es) 2023-04-17
CN116075499A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
CN116075499B (zh) 具有前药特性的新型脱磷酸裸盖菇素衍生物
CN112321566B (zh) Egfr蛋白降解剂及其抗肿瘤应用
EP3336097B1 (en) Preparation of the non-crystalline form of obeticholic acid
US10265325B2 (en) Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20230286975A1 (en) Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof
CN114728899A (zh) 新型三苯基化合物盐
CN106456618A (zh) 普多比啶类似物，其制备及用途
US20080261954A1 (en) Cholinergic Enhancers with Improved Blood-Brain Barrier permeability for the Treatment of Diseases Accompanied by Cognitive Impairment
US10550101B2 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
US7091354B2 (en) Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
CA3035312A1 (en) Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers
EP3774843B1 (en) Dipeptide piperidine derivatives
AU2023203345A1 (en) Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
EP2751094B1 (en) Novel crystal form
BR122026001062A2 (pt) Derivados de psilocina que apresentam propriedades pró-fármaco, seu uso e seu método de produção
EA051598B1 (ru) Новые производные псилоцина, обладающие свойствами пролекарств
CN101679256B (zh) 组蛋白脱乙酰酶抑制剂的单盐酸盐
US8710078B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
WO2022191092A1 (ja) キノリン化合物、ｈｎｍｔ阻害剤、及びａｄｈｄ、ナルコレプシー又はアルツハイマーの予防・治療剤
CN115124525A (zh) 含氮稠杂环化合物的盐的晶型及其制备方法和应用
CN113906016A (zh) 选择性组胺h3拮抗剂酸加成盐及其制备方法
NZ620864B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
HK1198534B (en) Novel crystal form

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant